GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spectral Medical Inc (OTCPK:EDTXF) » Definitions » Total Liabilities

EDTXF (Spectral Medical) Total Liabilities : $23.07 Mil (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Spectral Medical Total Liabilities?

Spectral Medical's Total Liabilities for the quarter that ended in Dec. 2024 was $23.07 Mil.

Spectral Medical's quarterly Total Liabilities increased from Jun. 2024 ($24.02 Mil) to Sep. 2024 ($29.16 Mil) but then declined from Sep. 2024 ($29.16 Mil) to Dec. 2024 ($23.07 Mil).

Spectral Medical's annual Total Liabilities increased from Dec. 2022 ($10.71 Mil) to Dec. 2023 ($16.22 Mil) and increased from Dec. 2023 ($16.22 Mil) to Dec. 2024 ($23.07 Mil).


Spectral Medical Total Liabilities Historical Data

The historical data trend for Spectral Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral Medical Total Liabilities Chart

Spectral Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.90 5.84 10.71 16.22 23.07

Spectral Medical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.22 18.49 24.02 29.16 23.07

Spectral Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Spectral Medical's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.264+(0.26+2.2204460492503E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.544+0+0)
=23.07

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=3.734--19.334
=23.07

Spectral Medical's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=19.264+(0.26+2.2204460492503E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+3.544+0+0)
=23.07

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=3.734--19.334
=23.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spectral Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Spectral Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectral Medical Business Description

Traded in Other Exchanges
Address
135 The West Mall, Unit 2, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation.